Bioequivalence of IMP 08P1707F0 Relative to Pulmicort® (1.0 Mg/2 Ml Suspension)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 13, 2024

Primary Completion Date

September 16, 2024

Study Completion Date

September 16, 2024

Conditions

Healthy

Interventions

DRUG

budesonide

Budesonide 1 mg/2mL nebuliser suspension

DRUG

budesonide

Pulmicort(r) 1 mg/2mL nebuliser suspension

OTHER

Activated Charcoal

suspension of 10g activated charcoal slurried in 70mL of water

Trial Locations (1)

Farmagen IKU Merkezi, Gaziantep

All Listed Sponsors

collaborator

Analytical Clinical Concepts (ACC GmbH)

UNKNOWN

lead

Unither Pharmaceuticals, France

INDUSTRY

NCT06595121 - Bioequivalence of IMP 08P1707F0 Relative to Pulmicort® (1.0 Mg/2 Ml Suspension) | Biotech Hunter | Biotech Hunter